A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma - Wikidata - thesis-toulmin - TriplyDB

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

http://www.wikidata.org/entity/Q36425427

about

Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy Immune Modulation in Hematologic Malignancies Strategies for combining immunotherapy with radiation for anticancer therapy Ly49 receptors: innate and adaptive immune paradigms Natural killer cell biology: an update and future directions Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Killer immunoglobulin-like receptors and tumor immunity Development of Novel Immunotherapies for Multiple Myeloma Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor Recent advances in understanding multiple myeloma Improving natural killer cell cancer immunotherapy Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.Immune checkpoint blockade for hematologic malignancies: a review Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Immune checkpoint inhibitors in clinical trials CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Present and Future of Allogeneic Natural Killer Cell Therapy Haematological malignancies: at the forefront of immunotherapeutic innovation.A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells.The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions Combination immune therapies to enhance anti-tumor responses by NK cells.MicroRNA-29b mediates altered innate immune development in acute leukemia.Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).MHC-dependent inhibition of uterine NK cells impedes fetal growth and decidual vascular remodelling.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy.Shaping of NK cell responses by the tumor microenvironment

P2860

Q26747397-12F657A6-57E4-4F7D-A944-544A5B33936D Q26751011-4CDD4B88-71D8-40A6-84F3-D5C9BCCF5647 Q26752518-73E899B1-F5FD-4D38-AEC7-6B93C2E63A50 Q26772347-691B03E1-110D-4351-9427-2D2FF400FF47 Q26796307-61FEF56F-5434-4775-BFC0-FCF8498943E8 Q26796675-0CE6F398-B947-4B30-A263-2E518837F783 Q26825078-FCA637E8-78B8-423B-A9EF-47B728CDF9CC Q26830512-76851582-5BAD-48F0-A65D-FBC63371F49E Q26996829-B9B2DACA-5F0A-4F3A-AFF4-B7CFC2AAD99C Q27001052-6687E848-1FFB-4A41-BDC0-68414E6A00EC Q27004421-E6216757-E6CB-4359-A49C-CF2671B81264 Q27005792-15E24CD2-87E0-403B-A951-870E2D228C78 Q28066890-4D57DF34-74A8-4111-A5AF-4CC31285D21B Q28067468-944422B7-2C01-48AC-A360-9229F619EA99 Q28070331-43F83B3B-9579-4974-BFE2-302F72E0D01F Q28087719-EB314567-32C1-4369-8A2E-E39CCF8155D7 Q28607344-02E4FFA5-B052-4419-B6D1-46C105B5C798 Q30275870-151EC0BC-8E03-4B93-B58F-BEFA02BF39C2 Q31118586-F778C26C-461B-475D-933E-961045422732 Q33645590-1BCE8CC4-DA26-4F51-9291-9EB7B349AE17 Q33770125-44ABA713-45CB-400E-8B9B-C8525706882D Q34309394-7841F2FD-3A19-447B-8298-D0D52D6FE2E5 Q34688644-D49BF92E-4CED-4A93-A159-7A324EE3EE51 Q35146307-1A0BB7FB-A125-40C8-8092-7A185926E0EF Q35600095-2A51CADD-677C-4094-8D61-EC8996145F65 Q35677351-7A857502-5AE9-48A0-8292-82121B9086E1 Q35880618-7181791C-F62D-4B3F-8F74-E8615061EAB8 Q36070261-2861671C-329D-439C-AFD6-131E3A5005AE Q36446188-39DB9F64-4432-4A9D-BDEE-415EC517F983 Q36691438-E1D673B0-8EF3-4EF5-A14F-EAEBB8B7162F Q36954166-D4C622C8-B4D7-4561-B4C4-A5B8FF78F020 Q37408550-47FF8CA4-74A8-4652-9DDF-BADCB0FC0FB4 Q37452181-147052E6-B06C-4AFB-BF47-1B6C227FB06A Q37535232-A66671BC-97E3-4295-98C0-D52A003AF401 Q37589671-89D84487-CFC7-4A64-AD89-B08726543A85 Q37627798-26897431-ECB9-4A26-B341-EA106D945FCE Q37652790-C939B0BE-C314-444C-A1B4-6F2D3EE6119D Q37666309-87234BDA-73B5-4A2C-9CCA-6AE3D7F48701 Q37739485-2BF7950A-128B-4908-9B59-6C28BA6FC5F4 Q38067641-D7F5DA45-D9C5-4876-9D03-99BD2A1F5F31

P2860

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

http://www.wikidata.org/entity/Q36425427

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

A phase 1 trial of the anti-KI ...... ed/refractory multiple myeloma

@ast

A phase 1 trial of the anti-KI ...... ed/refractory multiple myeloma

@en

type

label

A phase 1 trial of the anti-KI ...... ed/refractory multiple myeloma

@ast

A phase 1 trial of the anti-KI ...... ed/refractory multiple myeloma

@en

prefLabel

A phase 1 trial of the anti-KI ...... ed/refractory multiple myeloma

@ast

A phase 1 trial of the anti-KI ...... ed/refractory multiple myeloma

@en

P1433

Q36425427-328A607A-5D1C-45B8-A4FB-4CCADE570659

P1476

Q36425427-695B4225-9A61-4A91-B74E-48DA3ABF278E

P2093

Q36425427-083B547B-85F6-4C76-AA42-677283CDEE1D

Q36425427-26D4451A-62C7-4309-A4C7-4056820502C4

Q36425427-29D7142B-58F4-4A8D-94BA-C3B305C09505

Q36425427-4A20CE00-C6B3-4FAF-8C97-23788E8460C0

Q36425427-5F06020E-3E39-4D9F-A271-F961767528BE

Q36425427-964AF1A3-C970-4083-A5AF-6F48EE80F146

Q36425427-97BD8F79-4877-4ED1-9406-C629D51764E3

Q36425427-9BBADD84-9FC2-4B6A-AE4D-1439D34FAE66

Q36425427-B72AE11B-2ABF-4FC1-9E09-8445B64F0EE5

Q36425427-BC6FDE14-7025-4762-87C1-CB1D8FC3A729

P2860

Q36425427-05740AFC-F124-4E6A-805A-12894344B01F

Q36425427-153D7FA2-E44A-4FB1-AC63-C6C81F473282

Q36425427-167765F7-1B99-44CD-B319-C59DDC5F5EA2

Q36425427-2328EF94-7D66-4236-A826-92C84BB20FD9

Q36425427-2EBB9B7D-5E9F-42EA-9D85-9C3CAA01A1E1

Q36425427-49E54BF7-2495-440A-B4D5-0803BD4FFD4A

Q36425427-5B0B6012-0194-4106-AE7F-8F44279FBA19

Q36425427-6452D570-3BD7-4034-A750-BA82E9554ABD

Q36425427-6463E408-72AD-44AA-83B7-D53C43C8399D

Q36425427-67C0296D-1BA9-43F4-A7D1-96B7B934652B

P304

Q36425427-8FD0F069-3E69-4192-87B4-E95A7DFF3EA1

P31

Q36425427-6E09AED9-02B8-41B8-93C0-695E23D66512

P356

Q36425427-E980E273-5617-4262-8220-3D97028B1442

P407

Q36425427-3F661A2D-EA5A-4B24-863A-6670524E3B8D

P433

Q36425427-8CE0ECFA-D4D9-4167-9A91-62E837D7D0CB

P478

Q36425427-18DE8824-2427-4F7C-9EDB-023FCA4D3CE1

P577

Q36425427-B31A4FEE-14B9-4F6F-81EC-272E0D6FAD52

P5875

Q36425427-07E1781F-6421-4AA8-8368-BCCAAD2AC649

P698

Q36425427-BB7227C8-3E62-4F3E-8214-1123F47CB35A

P921

Q36425427-2A1E1C4B-0006-4A66-B22B-8BFD0E4F8D12

Q36425427-946D7016-76F4-4518-BD19-C3BC75864FE7

Q36425427-EEB00C61-6467-45F4-B37D-DDEEAB0CA5E2

P932

Q36425427-2537DC1D-55BA-4250-A5EF-593D9D9B750E

P356

BLOOD-2012-06-438028

P1433

P1476

A phase 1 trial of the anti-KI ...... ed/refractory multiple myeloma

@en

P2093

Attaya Suvannasankha

http://www.w3.org/2001/XMLSchema#string

Courtney Bakan

http://www.w3.org/2001/XMLSchema#string

Craig C Hofmeister

http://www.w3.org/2001/XMLSchema#string

Don M Benson

http://www.w3.org/2001/XMLSchema#string

Jérôme Tiollier

http://www.w3.org/2001/XMLSchema#string

Michael A Caligiuri

http://www.w3.org/2001/XMLSchema#string

Pascale Andre

http://www.w3.org/2001/XMLSchema#string

Rafat Abonour

http://www.w3.org/2001/XMLSchema#string

Sherif S Farag

http://www.w3.org/2001/XMLSchema#string

Sundar Jagannath

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

International uniform response criteria for multiple myeloma.

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect.

MHC class I molecules and KIRs in human history, health and survival.

Evidence for discrete stages of human natural killer cell differentiation in vivo

P304

4324-4333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-06-438028

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231864146

http://www.w3.org/2001/XMLSchema#string

P698

23033266

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3507143

http://www.w3.org/2001/XMLSchema#string